Exclusive Content
Cipla Partners with SBP Group for Next-Gen HER2 Cancer Therapy
Cipla Limited and Sino Biopharmaceutical Limited (SBP Group) announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), has entered into an exclusive license...
Eli Lilly to Acquire Merida Biosciences in $2.875B Deal to Advance Precision Immunology
Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, Inc., a privately held biotechnology company developing precision antibody-based therapies...
Ambuja Neotia Healthcare Announces Investment to Set Up 120-Bed Woman and Child Hospital in Howrah
Ambuja Neotia Healthcare Venture Ltd (ANHVL) has unveiled plans to establish a 120-bed specialized woman and child care hospital in Howrah, West Bengal, committing an investment...
AbbVie Submits Regulatory Application to EMA for Subcutaneous Induction of SKYRIZI®️ in Crohn’s Disease
AbbVie announced the submission of a regulatory application to the European Medicines Agency (EMA) seeking approval for SKYRIZI® (risankizumab) for subcutaneous (SC) induction dosing...
FDA Approves Takeda’s First-in-Class Therapy MIMRYLO for Polycythemia Vera Following Robust Phase 3 Results
Takeda announced that the U.S. Food and Drug Administration (FDA) has approved MIMRYLO, a first-in-class therapy indicated for the treatment of polycythemia vera. Polycythemiavera is a rare, chronic...
Maharashtra FDA Withdraws Drug License Cancellation Order for Cipla C&F Unit Following Bombay High Court Rebuke
In a major regulatory development, the Maharashtra Food and Drug Administration (FDA) has withdrawn its order cancelingthe drug sale license of Cipla Pharma & Life Sciences Ltd’sCarrying and...
